HOUSTON / LOS ANGELES — When Ozempic and Wegovy exploded onto the American health scene, they changed the conversation around obesity and diabetes forever. Millions of Americans — many in major cities where obesity rates climb well above the national average — rushed to get prescriptions. But for a significant number of patients, the side effects proved too difficult to bear: persistent nausea, vomiting, gastrointestinal distress, and a troubling loss of muscle mass.

Now, researchers at Karolinska Institutet and Stockholm University have published a study in the journal Cell describing a new oral compound that targets the same metabolic problems — but works in a completely different way.

▶ THE KEY DIFFERENCE

GLP-1 drugs like Ozempic work by mimicking gut hormones that signal the brain to reduce hunger. That's why they work — and also why they cause the side effects they do.

The new compound targets skeletal muscle directly. Rather than suppressing appetite, it activates metabolic pathways inside muscle cells, causing them to burn more fat and use glucose more efficiently. In animal studies, it improved both blood sugar control and body composition — more fat loss, preserved lean muscle mass.

In an early human clinical trial involving 48 healthy adults and 25 people with type 2 diabetes, the compound was found to be safe and well-tolerated, with fewer cardiovascular side effects than traditional beta-2 agonists.

▶ WHY AMERICA NEEDS THIS

Obesity now affects more than 42% of American adults, according to the CDC. In the nation's largest cities, the situation is particularly acute. Houston consistently ranks among the most obese large cities in the United States. In Los Angeles, obesity-related type 2 diabetes affects hundreds of thousands of residents, straining county health systems already operating near capacity.

For these patients, the promise of a pill — not an injection — that burns fat without eliminating appetite or eroding muscle could represent a genuinely better option.

Read more

▶ THE SCIENCE BEHIND THE PILL

The compound is a selective beta-2 adrenergic receptor agonist — a class of drug previously used in respiratory medicine but now being engineered to target metabolism in muscle. The researchers designed it to be highly selective for muscle tissue, avoiding the cardiovascular effects that made older beta-2 agonists dangerous.

"This makes it valuable both as a stand-alone treatment and in combination with GLP-1 drugs," said Shane Wright, a co-author of the study. For patients who want the metabolic benefits of modern weight-loss drugs without the GI-related side effects, a combination approach could offer the best of both worlds.

▶ WHAT HAPPENS NEXT

The company behind the drug, Atrogi AB, plans to conduct a larger Phase 2 clinical trial involving a more diverse population, including individuals with obesity. Researchers expect that trial to better reflect the demographics of cities like Los Angeles, Houston, and New York — places where obesity intersects with disparities in income, food access, and healthcare.

Adding urgency to the development timeline: Medicare Part D is set to launch coverage for GLP-1 drugs for weight loss under the CMS BALANCE Model starting July 1, 2026, meaning millions more Americans will soon have insurance access to this class of medication. A pill-based alternative — easier to prescribe, easier to take, and better tolerated — could transform uptake rates among patients who previously declined injectable therapies.

For a nation wrestling with an obesity epidemic that costs roughly $173 billion per year in healthcare expenditures, the arrival of a new metabolic drug with fewer side effects is not just good science. It is good news.